# PeptideScanner evidence objects: Peginesatide

Every published version of the records placed with Peginesatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/peginesatide.json. Selected public evidence only; not medical advice.

- Objects: 34
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00097747-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00097747

> PeptideScanner retained ClinicalTrials.gov record NCT00097747 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00097747-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-12-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00097747-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00097747-peginesatide-v1
- Content SHA-256: `357064512fbb02b4504acab8582fea53450510e1bc55f6da0b7a5bff24e137f2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00097747 ([`ctg-observation-nct00097747-2012-12-21-94d632b0d309`](#source-ctg-observation-nct00097747-2012-12-21-94d632b0d309))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00097747 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00097747-2012-12-21-94d632b0d309`](#source-ctg-observation-nct00097747-2012-12-21-94d632b0d309))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00097747 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00097747-2012-12-21-94d632b0d309`](#source-ctg-observation-nct00097747-2012-12-21-94d632b0d309))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00097747-2012-12-21-94d632b0d309`](#source-ctg-observation-nct00097747-2012-12-21-94d632b0d309))

### Sources

<a id="source-ctg-observation-nct00097747-2012-12-21-94d632b0d309"></a>
- **ClinicalTrials.gov record NCT00097747 · retained source version 2012-12-21:94d632b0d30932e9d83b65f0becd193cea0dd9eb7ac85909f4f7cfda4cb10d98** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00097747) (`ctg-observation-nct00097747-2012-12-21-94d632b0d309`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00097747." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00097747-peginesatide-v1 SHA-256: 357064512fbb02b4504acab8582fea53450510e1bc55f6da0b7a5bff24e137f2.

---

<a id="clinicaltrials-gov-nct00228436-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00228436

> PeptideScanner retained ClinicalTrials.gov record NCT00228436 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00228436-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-12-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00228436-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00228436-peginesatide-v1
- Content SHA-256: `bc3b797f5e140077915a9771ac8b58495e5aee0984bab20a21b2470b37e2a9b0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00228436 ([`ctg-observation-nct00228436-2012-12-21-d79c980635eb`](#source-ctg-observation-nct00228436-2012-12-21-d79c980635eb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00228436 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00228436-2012-12-21-d79c980635eb`](#source-ctg-observation-nct00228436-2012-12-21-d79c980635eb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00228436 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00228436-2012-12-21-d79c980635eb`](#source-ctg-observation-nct00228436-2012-12-21-d79c980635eb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00228436-2012-12-21-d79c980635eb`](#source-ctg-observation-nct00228436-2012-12-21-d79c980635eb))

### Sources

<a id="source-ctg-observation-nct00228436-2012-12-21-d79c980635eb"></a>
- **ClinicalTrials.gov record NCT00228436 · retained source version 2012-12-21:d79c980635ebdd8814535d643f53ffd9349bc3c3425ce0477431a1fe5bf169e4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00228436) (`ctg-observation-nct00228436-2012-12-21-d79c980635eb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00228436." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00228436-peginesatide-v1 SHA-256: bc3b797f5e140077915a9771ac8b58495e5aee0984bab20a21b2470b37e2a9b0.

---

<a id="clinicaltrials-gov-nct00228449-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00228449

> PeptideScanner retained ClinicalTrials.gov record NCT00228449 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00228449-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-12-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00228449-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00228449-peginesatide-v1
- Content SHA-256: `af4f351d80d538f317649d072102009bdd0e5c58e25ea38478c1e3a75ef39e1d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00228449 ([`ctg-observation-nct00228449-2012-12-21-640e1fc45578`](#source-ctg-observation-nct00228449-2012-12-21-640e1fc45578))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00228449 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00228449-2012-12-21-640e1fc45578`](#source-ctg-observation-nct00228449-2012-12-21-640e1fc45578))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00228449 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00228449-2012-12-21-640e1fc45578`](#source-ctg-observation-nct00228449-2012-12-21-640e1fc45578))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00228449-2012-12-21-640e1fc45578`](#source-ctg-observation-nct00228449-2012-12-21-640e1fc45578))

### Sources

<a id="source-ctg-observation-nct00228449-2012-12-21-640e1fc45578"></a>
- **ClinicalTrials.gov record NCT00228449 · retained source version 2012-12-21:640e1fc455783fb9f5b76c964473b2522548a21cca10cbb2bc6306e3a5359e8e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00228449) (`ctg-observation-nct00228449-2012-12-21-640e1fc45578`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00228449." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00228449-peginesatide-v1 SHA-256: af4f351d80d538f317649d072102009bdd0e5c58e25ea38478c1e3a75ef39e1d.

---

<a id="clinicaltrials-gov-nct00272662-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00272662

> PeptideScanner retained ClinicalTrials.gov record NCT00272662 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00272662-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-12-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00272662-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00272662-peginesatide-v1
- Content SHA-256: `83956cf7d22d2cb5b43dc52cf7b8c04fa50a4406d05d35f837ac34476bc4ff56`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00272662 ([`ctg-observation-nct00272662-2012-12-21-7ce33d809436`](#source-ctg-observation-nct00272662-2012-12-21-7ce33d809436))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00272662 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00272662-2012-12-21-7ce33d809436`](#source-ctg-observation-nct00272662-2012-12-21-7ce33d809436))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00272662 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-12-21, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00272662-2012-12-21-7ce33d809436`](#source-ctg-observation-nct00272662-2012-12-21-7ce33d809436))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00272662-2012-12-21-7ce33d809436`](#source-ctg-observation-nct00272662-2012-12-21-7ce33d809436))

### Sources

<a id="source-ctg-observation-nct00272662-2012-12-21-7ce33d809436"></a>
- **ClinicalTrials.gov record NCT00272662 · retained source version 2012-12-21:7ce33d80943644f9f1d381593bc71555003363161584765347ac05833e1cd2aa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00272662) (`ctg-observation-nct00272662-2012-12-21-7ce33d809436`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00272662." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00272662-peginesatide-v1 SHA-256: 83956cf7d22d2cb5b43dc52cf7b8c04fa50a4406d05d35f837ac34476bc4ff56.

---

<a id="clinicaltrials-gov-nct00314795-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00314795

> PeptideScanner retained ClinicalTrials.gov record NCT00314795 at 2026-11-16T17:45:11.119Z. Its registry update date was 2019-03-14, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00314795-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-03-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00314795-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00314795-peginesatide-v1
- Content SHA-256: `2bd93cf3673aab4ededb3fecc40ec3b27289b0c9610b05a409022f4a3765a61e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00314795 ([`ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a`](#source-ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00314795 at 2026-11-16T17:45:11.119Z. Its registry update date was 2019-03-14, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a`](#source-ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00314795 at 2026-11-16T17:45:11.119Z. Its registry update date was 2019-03-14, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a`](#source-ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a`](#source-ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a))

### Sources

<a id="source-ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a"></a>
- **ClinicalTrials.gov record NCT00314795 · retained source version 2019-03-14:1c2bd2cbee5a6c6ca3c2fa332f5a27e678f462899f0351b1c404e3bdbec744b0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00314795) (`ctg-observation-nct00314795-2019-03-14-1c2bd2cbee5a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00314795." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00314795-peginesatide-v1 SHA-256: 2bd93cf3673aab4ededb3fecc40ec3b27289b0c9610b05a409022f4a3765a61e.

---

<a id="clinicaltrials-gov-nct00434330-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00434330

> PeptideScanner retained ClinicalTrials.gov record NCT00434330 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00434330-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-06-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00434330-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00434330-peginesatide-v1
- Content SHA-256: `9cea56e6ee2f615dabc5ab28ed9ea6e5ec47947ee2d288d9d96d9da5db466c0b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00434330 ([`ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809`](#source-ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00434330 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809`](#source-ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00434330 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809`](#source-ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809`](#source-ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809))

### Sources

<a id="source-ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809"></a>
- **ClinicalTrials.gov record NCT00434330 · retained source version 2012-06-29:aa3ddbd6a809e27e4078df9385866a2970cabb930eb0e9a67ae3cda03d5f38ec** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00434330) (`ctg-observation-nct00434330-2012-06-29-aa3ddbd6a809`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00434330." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00434330-peginesatide-v1 SHA-256: 9cea56e6ee2f615dabc5ab28ed9ea6e5ec47947ee2d288d9d96d9da5db466c0b.

---

<a id="clinicaltrials-gov-nct00597584-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00597584

> PeptideScanner retained ClinicalTrials.gov record NCT00597584 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00597584-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-03-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00597584-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00597584-peginesatide-v1
- Content SHA-256: `4a5f220bb0ef222e9f5ea39a9cd7031dfb7d1e35c27ba19a77b7ab1bacb30b5a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00597584 ([`ctg-observation-nct00597584-2013-03-08-fdbfc6373e59`](#source-ctg-observation-nct00597584-2013-03-08-fdbfc6373e59))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00597584 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00597584-2013-03-08-fdbfc6373e59`](#source-ctg-observation-nct00597584-2013-03-08-fdbfc6373e59))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00597584 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00597584-2013-03-08-fdbfc6373e59`](#source-ctg-observation-nct00597584-2013-03-08-fdbfc6373e59))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00597584-2013-03-08-fdbfc6373e59`](#source-ctg-observation-nct00597584-2013-03-08-fdbfc6373e59))

### Sources

<a id="source-ctg-observation-nct00597584-2013-03-08-fdbfc6373e59"></a>
- **ClinicalTrials.gov record NCT00597584 · retained source version 2013-03-08:fdbfc6373e598b4814cdb52de6c2d23028240b618f407eaf1cb887136ef6218d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00597584) (`ctg-observation-nct00597584-2013-03-08-fdbfc6373e59`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00597584." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00597584-peginesatide-v1 SHA-256: 4a5f220bb0ef222e9f5ea39a9cd7031dfb7d1e35c27ba19a77b7ab1bacb30b5a.

---

<a id="clinicaltrials-gov-nct00597753-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00597753

> PeptideScanner retained ClinicalTrials.gov record NCT00597753 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00597753-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-02-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00597753-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00597753-peginesatide-v1
- Content SHA-256: `fe1f0459a7ed3e2e63dece215d919e0a2aad6be98334ed5d726cea1265c19a36`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00597753 ([`ctg-observation-nct00597753-2013-02-12-f30eace3c272`](#source-ctg-observation-nct00597753-2013-02-12-f30eace3c272))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00597753 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00597753-2013-02-12-f30eace3c272`](#source-ctg-observation-nct00597753-2013-02-12-f30eace3c272))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00597753 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00597753-2013-02-12-f30eace3c272`](#source-ctg-observation-nct00597753-2013-02-12-f30eace3c272))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00597753-2013-02-12-f30eace3c272`](#source-ctg-observation-nct00597753-2013-02-12-f30eace3c272))

### Sources

<a id="source-ctg-observation-nct00597753-2013-02-12-f30eace3c272"></a>
- **ClinicalTrials.gov record NCT00597753 · retained source version 2013-02-12:f30eace3c27265c0f357deac9ffbfd13bcfa1e36f19b18459767727a21b2f5fb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00597753) (`ctg-observation-nct00597753-2013-02-12-f30eace3c272`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00597753." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00597753-peginesatide-v1 SHA-256: fe1f0459a7ed3e2e63dece215d919e0a2aad6be98334ed5d726cea1265c19a36.

---

<a id="clinicaltrials-gov-nct00598273-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00598273

> PeptideScanner retained ClinicalTrials.gov record NCT00598273 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00598273-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-02-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00598273-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00598273-peginesatide-v1
- Content SHA-256: `c39eb67d035a8d70b89b42b05849570d94cf7b3076485d7fb37ddaa0dd54cead`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00598273 ([`ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53`](#source-ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00598273 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53`](#source-ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00598273 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53`](#source-ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53`](#source-ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53))

### Sources

<a id="source-ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53"></a>
- **ClinicalTrials.gov record NCT00598273 · retained source version 2013-02-12:28fe8bf9ee537c54227b56fe0e0aed4ffdae3a85541d35c8f63304eb7bf9e81f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00598273) (`ctg-observation-nct00598273-2013-02-12-28fe8bf9ee53`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00598273." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00598273-peginesatide-v1 SHA-256: c39eb67d035a8d70b89b42b05849570d94cf7b3076485d7fb37ddaa0dd54cead.

---

<a id="clinicaltrials-gov-nct00598442-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00598442

> PeptideScanner retained ClinicalTrials.gov record NCT00598442 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00598442-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-02-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00598442-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00598442-peginesatide-v1
- Content SHA-256: `13acf95f862972f3bcc8b6fe50a99545ae1a43334be27554c48b968b857b02d2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00598442 ([`ctg-observation-nct00598442-2013-02-12-961162cb85af`](#source-ctg-observation-nct00598442-2013-02-12-961162cb85af))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00598442 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00598442-2013-02-12-961162cb85af`](#source-ctg-observation-nct00598442-2013-02-12-961162cb85af))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00598442 at 2026-11-16T17:45:11.119Z. Its registry update date was 2013-02-12, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00598442-2013-02-12-961162cb85af`](#source-ctg-observation-nct00598442-2013-02-12-961162cb85af))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00598442-2013-02-12-961162cb85af`](#source-ctg-observation-nct00598442-2013-02-12-961162cb85af))

### Sources

<a id="source-ctg-observation-nct00598442-2013-02-12-961162cb85af"></a>
- **ClinicalTrials.gov record NCT00598442 · retained source version 2013-02-12:961162cb85afa994730788184d79e314792ce06ba31e215f9360c08261360cda** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00598442) (`ctg-observation-nct00598442-2013-02-12-961162cb85af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00598442." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00598442-peginesatide-v1 SHA-256: 13acf95f862972f3bcc8b6fe50a99545ae1a43334be27554c48b968b857b02d2.

---

<a id="clinicaltrials-gov-nct00680043-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00680043

> PeptideScanner retained ClinicalTrials.gov record NCT00680043 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00680043-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-06-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00680043-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00680043-peginesatide-v1
- Content SHA-256: `7622fc58b172c70347498be420a42ff3457a07512a25b9140412c25d049c1505`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00680043 ([`ctg-observation-nct00680043-2012-06-29-d3db87297425`](#source-ctg-observation-nct00680043-2012-06-29-d3db87297425))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00680043 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00680043-2012-06-29-d3db87297425`](#source-ctg-observation-nct00680043-2012-06-29-d3db87297425))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00680043 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-06-29, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00680043-2012-06-29-d3db87297425`](#source-ctg-observation-nct00680043-2012-06-29-d3db87297425))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00680043-2012-06-29-d3db87297425`](#source-ctg-observation-nct00680043-2012-06-29-d3db87297425))

### Sources

<a id="source-ctg-observation-nct00680043-2012-06-29-d3db87297425"></a>
- **ClinicalTrials.gov record NCT00680043 · retained source version 2012-06-29:d3db87297425c593bbe09a04d120b85df6bed28d7714146ca6a71a462746d5d0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00680043) (`ctg-observation-nct00680043-2012-06-29-d3db87297425`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00680043." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00680043-peginesatide-v1 SHA-256: 7622fc58b172c70347498be420a42ff3457a07512a25b9140412c25d049c1505.

---

<a id="clinicaltrials-gov-nct00752609-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00752609

> PeptideScanner retained ClinicalTrials.gov record NCT00752609 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-07-27, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00752609-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-07-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00752609-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00752609-peginesatide-v1
- Content SHA-256: `1cbb8d0b86b56a54cedabab9e266aba38b407064971857140b028f84d45a2e0a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00752609 ([`ctg-observation-nct00752609-2012-07-27-664b1ad23677`](#source-ctg-observation-nct00752609-2012-07-27-664b1ad23677))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00752609 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-07-27, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00752609-2012-07-27-664b1ad23677`](#source-ctg-observation-nct00752609-2012-07-27-664b1ad23677))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00752609 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-07-27, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00752609-2012-07-27-664b1ad23677`](#source-ctg-observation-nct00752609-2012-07-27-664b1ad23677))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00752609-2012-07-27-664b1ad23677`](#source-ctg-observation-nct00752609-2012-07-27-664b1ad23677))

### Sources

<a id="source-ctg-observation-nct00752609-2012-07-27-664b1ad23677"></a>
- **ClinicalTrials.gov record NCT00752609 · retained source version 2012-07-27:664b1ad23677e98e3d3d6f9641ca9536406b199e34712677bc5d9679a9ab3082** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00752609) (`ctg-observation-nct00752609-2012-07-27-664b1ad23677`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00752609." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00752609-peginesatide-v1 SHA-256: 1cbb8d0b86b56a54cedabab9e266aba38b407064971857140b028f84d45a2e0a.

---

<a id="clinicaltrials-gov-nct00752791-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT00752791

> PeptideScanner retained ClinicalTrials.gov record NCT00752791 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-08-15, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct00752791-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-08-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00752791-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00752791-peginesatide-v1
- Content SHA-256: `e9c06fd88f3382134d4c3d73c28ebf3a4d17c595370a59dba5636bec7bcc5d82`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00752791 ([`ctg-observation-nct00752791-2012-08-15-86b30643d3fa`](#source-ctg-observation-nct00752791-2012-08-15-86b30643d3fa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00752791 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-08-15, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00752791-2012-08-15-86b30643d3fa`](#source-ctg-observation-nct00752791-2012-08-15-86b30643d3fa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00752791 at 2026-11-16T17:45:11.119Z. Its registry update date was 2012-08-15, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct00752791-2012-08-15-86b30643d3fa`](#source-ctg-observation-nct00752791-2012-08-15-86b30643d3fa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00752791-2012-08-15-86b30643d3fa`](#source-ctg-observation-nct00752791-2012-08-15-86b30643d3fa))

### Sources

<a id="source-ctg-observation-nct00752791-2012-08-15-86b30643d3fa"></a>
- **ClinicalTrials.gov record NCT00752791 · retained source version 2012-08-15:86b30643d3fa54f8b252e834df750d8347b00abcdfb5a791858801136a75dcbe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00752791) (`ctg-observation-nct00752791-2012-08-15-86b30643d3fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00752791." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct00752791-peginesatide-v1 SHA-256: e9c06fd88f3382134d4c3d73c28ebf3a4d17c595370a59dba5636bec7bcc5d82.

---

<a id="clinicaltrials-gov-nct01478971-peginesatide-v1"></a>

## ClinicalTrials.gov record NCT01478971

> PeptideScanner retained ClinicalTrials.gov record NCT01478971 at 2026-11-16T17:45:11.119Z. Its registry update date was 2016-09-20, and PeptideScanner's reviewed identity mapping was peginesatide.

- Evidence object: `story:clinicaltrials-gov-nct01478971-peginesatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-09-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01478971-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct01478971-peginesatide-v1
- Content SHA-256: `066f10add7cae2cb312e116592bfc7f001b208740a16390b10d957c0154a3ee8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01478971 ([`ctg-observation-nct01478971-2016-09-20-f9be6822258a`](#source-ctg-observation-nct01478971-2016-09-20-f9be6822258a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01478971 at 2026-11-16T17:45:11.119Z. Its registry update date was 2016-09-20, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct01478971-2016-09-20-f9be6822258a`](#source-ctg-observation-nct01478971-2016-09-20-f9be6822258a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01478971 at 2026-11-16T17:45:11.119Z. Its registry update date was 2016-09-20, and PeptideScanner's reviewed identity mapping was peginesatide. ([`ctg-observation-nct01478971-2016-09-20-f9be6822258a`](#source-ctg-observation-nct01478971-2016-09-20-f9be6822258a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01478971-2016-09-20-f9be6822258a`](#source-ctg-observation-nct01478971-2016-09-20-f9be6822258a))

### Sources

<a id="source-ctg-observation-nct01478971-2016-09-20-f9be6822258a"></a>
- **ClinicalTrials.gov record NCT01478971 · retained source version 2016-09-20:f9be6822258a932ab7f2d3ec7acddf879ee628aecbda545a3192d03522b30cbe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01478971) (`ctg-observation-nct01478971-2016-09-20-f9be6822258a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01478971." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#clinicaltrials-gov-nct01478971-peginesatide-v1 SHA-256: 066f10add7cae2cb312e116592bfc7f001b208740a16390b10d957c0154a3ee8.

---

<a id="fda-drugs-nda202799-v1"></a>

## Drugs@FDA application NDA202799

> The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda202799:v1`
- Evidence domain: Regulatory
- Date in source: 2012-03-27
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda202799/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#fda-drugs-nda202799-v1
- Content SHA-256: `b983e932de91d3959fec3f25890a10aaf11151456af439b3fc274d563494e6d5`

### Claims and source pins

#### Headline

Drugs@FDA application NDA202799 ([`fda-drugs-nda202799-2012-03-27-02eb35891ff6`](#source-fda-drugs-nda202799-2012-03-27-02eb35891ff6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients. ([`fda-drugs-nda202799-2012-03-27-02eb35891ff6`](#source-fda-drugs-nda202799-2012-03-27-02eb35891ff6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients. ([`fda-drugs-nda202799-2012-03-27-02eb35891ff6`](#source-fda-drugs-nda202799-2012-03-27-02eb35891ff6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda202799-2012-03-27-02eb35891ff6`](#source-fda-drugs-nda202799-2012-03-27-02eb35891ff6))

### Sources

<a id="source-fda-drugs-nda202799-2012-03-27-02eb35891ff6"></a>
- **Drugs@FDA application NDA202799 · original submission status AP · 2012-03-27 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA202799%22&limit=1) (`fda-drugs-nda202799-2012-03-27-02eb35891ff6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA202799." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#fda-drugs-nda202799-v1 SHA-256: b983e932de91d3959fec3f25890a10aaf11151456af439b3fc274d563494e6d5.

---

<a id="federal-register-2011-27327-v1"></a>

## Federal Register notice 2011-27327

> The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

- Evidence object: `story:federal-register-2011-27327:v1`
- Evidence domain: Regulatory
- Date in source: 2011-10-24
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2011-27327/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#federal-register-2011-27327-v1
- Content SHA-256: `d56c7091b9632cf8aafe7ca114f7643bcb08ef9b7a16e54428cce6859e204b4a`

### Claims and source pins

#### Headline

Federal Register notice 2011-27327 ([`federal-register-2011-27327-0d5a3ae35e5d`](#source-federal-register-2011-27327-0d5a3ae35e5d))

#### Summary

The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide. ([`federal-register-2011-27327-0d5a3ae35e5d`](#source-federal-register-2011-27327-0d5a3ae35e5d))

#### Paragraph 1

The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide. ([`federal-register-2011-27327-0d5a3ae35e5d`](#source-federal-register-2011-27327-0d5a3ae35e5d))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2011-27327-0d5a3ae35e5d`](#source-federal-register-2011-27327-0d5a3ae35e5d))

### Sources

<a id="source-federal-register-2011-27327-0d5a3ae35e5d"></a>
- **Federal Register notice 2011-27327 · published 2011-10-24 · Oncologic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2011-10-24/pdf/2011-27327.pdf) (`federal-register-2011-27327-0d5a3ae35e5d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2011-27327." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#federal-register-2011-27327-v1 SHA-256: d56c7091b9632cf8aafe7ca114f7643bcb08ef9b7a16e54428cce6859e204b4a.

---

<a id="federal-register-2014-11523-v1"></a>

## Federal Register notice 2014-11523

> The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

- Evidence object: `story:federal-register-2014-11523:v1`
- Evidence domain: Regulatory
- Date in source: 2014-05-20
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-11523/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#federal-register-2014-11523-v1
- Content SHA-256: `72ef41ba64d92cae4ddef1141952962f4d660f55332dee030c7799f577551d91`

### Claims and source pins

#### Headline

Federal Register notice 2014-11523 ([`federal-register-2014-11523-b0c303a07802`](#source-federal-register-2014-11523-b0c303a07802))

#### Summary

The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide. ([`federal-register-2014-11523-b0c303a07802`](#source-federal-register-2014-11523-b0c303a07802))

#### Paragraph 1

The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide. ([`federal-register-2014-11523-b0c303a07802`](#source-federal-register-2014-11523-b0c303a07802))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-11523-b0c303a07802`](#source-federal-register-2014-11523-b0c303a07802))

### Sources

<a id="source-federal-register-2014-11523-b0c303a07802"></a>
- **Federal Register notice 2014-11523 · published 2014-05-20 · Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-05-20/pdf/2014-11523.pdf) (`federal-register-2014-11523-b0c303a07802`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-11523." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#federal-register-2014-11523-v1 SHA-256: 72ef41ba64d92cae4ddef1141952962f4d660f55332dee030c7799f577551d91.

---

<a id="federal-register-2019-02146-v1"></a>

## Federal Register notice 2019-02146

> The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

- Evidence object: `story:federal-register-2019-02146:v1`
- Evidence domain: Regulatory
- Date in source: 2019-02-13
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-02146/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#federal-register-2019-02146-v1
- Content SHA-256: `4136406c2182a586430dab55593288d6c64f9d7458f9d41430e31a3599cd92c3`

### Claims and source pins

#### Headline

Federal Register notice 2019-02146 ([`federal-register-2019-02146-8c1eb3bcb948`](#source-federal-register-2019-02146-8c1eb3bcb948))

#### Summary

The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide. ([`federal-register-2019-02146-8c1eb3bcb948`](#source-federal-register-2019-02146-8c1eb3bcb948))

#### Paragraph 1

The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide. ([`federal-register-2019-02146-8c1eb3bcb948`](#source-federal-register-2019-02146-8c1eb3bcb948))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-02146-8c1eb3bcb948`](#source-federal-register-2019-02146-8c1eb3bcb948))

### Sources

<a id="source-federal-register-2019-02146-8c1eb3bcb948"></a>
- **Federal Register notice 2019-02146 · published 2019-02-13 · Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-02-13/pdf/2019-02146.pdf) (`federal-register-2019-02146-8c1eb3bcb948`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2019-02146." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#federal-register-2019-02146-v1 SHA-256: 4136406c2182a586430dab55593288d6c64f9d7458f9d41430e31a3599cd92c3.

---

<a id="pubmed-pmid-21816551-peginesatide-v1"></a>

## Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples.

> PubMed lists PMID 21816551 in Forensic science international as Journal Article, with publication-date metadata of 2011-08-03 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21816551-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21816551-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-21816551-peginesatide-v1
- Content SHA-256: `737231c5a87df384a22cb363c9a8cd05fdf03a1e82f5c713f3d12a4729f1d2e6`

### Claims and source pins

#### Headline

Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples. ([`pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f`](#source-pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f))

#### Summary

PubMed lists PMID 21816551 in Forensic science international as Journal Article, with publication-date metadata of 2011-08-03 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f`](#source-pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f))

#### Paragraph 1

PubMed lists PMID 21816551 in Forensic science international as Journal Article, with publication-date metadata of 2011-08-03 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f`](#source-pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f`](#source-pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f))

### Sources

<a id="source-pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f"></a>
- **Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples. · retained source version 1:2017-11-16:current:5f09a642fa6f0ddb67a388aebff9b89aca8056a7595caac66d372381da801773** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21816551/) (`pubmed-observation-pmid-21816551-2017-11-16-5f09a642fa6f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-21816551-peginesatide-v1 SHA-256: 737231c5a87df384a22cb363c9a8cd05fdf03a1e82f5c713f3d12a4729f1d2e6.

---

<a id="pubmed-pmid-22592927-peginesatide-v1"></a>

## Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing.

> PubMed lists PMID 22592927 in Analytical and bioanalytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, Validation Study, with publication-date metadata of 2012-05-17 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22592927-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22592927-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-22592927-peginesatide-v1
- Content SHA-256: `60b51ff2007e2f20c1b5605aaa556665f8b7887f3018c1b1c28aaa874d666cf7`

### Claims and source pins

#### Headline

Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. ([`pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133`](#source-pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133))

#### Summary

PubMed lists PMID 22592927 in Analytical and bioanalytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, Validation Study, with publication-date metadata of 2012-05-17 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133`](#source-pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133))

#### Paragraph 1

PubMed lists PMID 22592927 in Analytical and bioanalytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, Validation Study, with publication-date metadata of 2012-05-17 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133`](#source-pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133`](#source-pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133))

### Sources

<a id="source-pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133"></a>
- **Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. · retained source version 1:2019-12-10:current:8d1f70631133616796877c199150f7f7789d56e08dd1c580ee048d584101a9b1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22592927/) (`pubmed-observation-pmid-22592927-2019-12-10-8d1f70631133`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-22592927-peginesatide-v1 SHA-256: 60b51ff2007e2f20c1b5605aaa556665f8b7887f3018c1b1c28aaa874d666cf7.

---

<a id="pubmed-pmid-22683926-peginesatide-v1"></a>

## Peginesatide (Omontys) for anemia in chronic kidney failure.

> PubMed lists PMID 22683926 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2012-06-11 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22683926-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22683926-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-22683926-peginesatide-v1
- Content SHA-256: `06e35b89acaffda9b55eaf7d4060341ae611799c3e87170139e258c718959843`

### Claims and source pins

#### Headline

Peginesatide (Omontys) for anemia in chronic kidney failure. ([`pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab`](#source-pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab))

#### Summary

PubMed lists PMID 22683926 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2012-06-11 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab`](#source-pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab))

#### Paragraph 1

PubMed lists PMID 22683926 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2012-06-11 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab`](#source-pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab`](#source-pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab))

### Sources

<a id="source-pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab"></a>
- **Peginesatide (Omontys) for anemia in chronic kidney failure. · retained source version 1:2026-01-28:current:06808a4e50abc77dc5f6a9f2bfb0f807871f339b71bcf1ea60a3abd030b8dd54** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22683926/) (`pubmed-observation-pmid-22683926-2026-01-28-06808a4e50ab`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide (Omontys) for anemia in chronic kidney failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-22683926-peginesatide-v1 SHA-256: 06e35b89acaffda9b55eaf7d4060341ae611799c3e87170139e258c718959843.

---

<a id="pubmed-pmid-22745925-peginesatide-v1"></a>

## Peginesatide for the treatment of anemia in the nephrology setting.

> PubMed lists PMID 22745925 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, with publication-date metadata of 2012-06 (month precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22745925-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22745925-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-22745925-peginesatide-v1
- Content SHA-256: `51868b0fa06c52aa7734cc8bd0d6ba282ae87b22a23bc9de69c3a4c11cbabcce`

### Claims and source pins

#### Headline

Peginesatide for the treatment of anemia in the nephrology setting. ([`pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b`](#source-pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b))

#### Summary

PubMed lists PMID 22745925 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, with publication-date metadata of 2012-06 (month precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b`](#source-pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b))

#### Paragraph 1

PubMed lists PMID 22745925 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, with publication-date metadata of 2012-06 (month precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b`](#source-pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b`](#source-pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b))

### Sources

<a id="source-pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b"></a>
- **Peginesatide for the treatment of anemia in the nephrology setting. · retained source version 1:2018-12-01:current:bcb406c7320bfa3ca9da5a31bcdcd323f819db32477d1200e6c57a8ec901124c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22745925/) (`pubmed-observation-pmid-22745925-2018-12-01-bcb406c7320b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide for the treatment of anemia in the nephrology setting." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-22745925-peginesatide-v1 SHA-256: 51868b0fa06c52aa7734cc8bd0d6ba282ae87b22a23bc9de69c3a4c11cbabcce.

---

<a id="pubmed-pmid-23023854-peginesatide-v1"></a>

## Peginesatide acetate, axitinib, and pertuzumab.

> PubMed lists PMID 23023854 in Journal of the American Pharmacists Association : JAPhA as Journal Article, Review, with publication-date metadata of 2012 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23023854-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23023854-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23023854-peginesatide-v1
- Content SHA-256: `b8992233d8cffd3532845ea69cb0e0bb236e0d0f5b771db7424a238d21d06bca`

### Claims and source pins

#### Headline

Peginesatide acetate, axitinib, and pertuzumab. ([`pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af`](#source-pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af))

#### Summary

PubMed lists PMID 23023854 in Journal of the American Pharmacists Association : JAPhA as Journal Article, Review, with publication-date metadata of 2012 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af`](#source-pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af))

#### Paragraph 1

PubMed lists PMID 23023854 in Journal of the American Pharmacists Association : JAPhA as Journal Article, Review, with publication-date metadata of 2012 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af`](#source-pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af`](#source-pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af))

### Sources

<a id="source-pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af"></a>
- **Peginesatide acetate, axitinib, and pertuzumab. · retained source version 1:2026-11-09:current:09dc80e204af3dbb6e448df862457bc8d9a5bd3bb8416c2af88908392edf01f6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23023854/) (`pubmed-observation-pmid-23023854-2026-11-09-09dc80e204af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide acetate, axitinib, and pertuzumab." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23023854-peginesatide-v1 SHA-256: b8992233d8cffd3532845ea69cb0e0bb236e0d0f5b771db7424a238d21d06bca.

---

<a id="pubmed-pmid-23243269-peginesatide-v1"></a>

## Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa.

> PubMed lists PMID 23243269 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-12-14 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23243269-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23243269-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23243269-peginesatide-v1
- Content SHA-256: `1ed287be9f8cb90d55e4e1b5c612f7a8f60c11432b850c10eaa8e7b4612d57ed`

### Claims and source pins

#### Headline

Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. ([`pubmed-observation-pmid-23243269-2021-10-21-160405f6760a`](#source-pubmed-observation-pmid-23243269-2021-10-21-160405f6760a))

#### Summary

PubMed lists PMID 23243269 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-12-14 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23243269-2021-10-21-160405f6760a`](#source-pubmed-observation-pmid-23243269-2021-10-21-160405f6760a))

#### Paragraph 1

PubMed lists PMID 23243269 in Clinical journal of the American Society of Nephrology : CJASN as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-12-14 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23243269-2021-10-21-160405f6760a`](#source-pubmed-observation-pmid-23243269-2021-10-21-160405f6760a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23243269-2021-10-21-160405f6760a`](#source-pubmed-observation-pmid-23243269-2021-10-21-160405f6760a))

### Sources

<a id="source-pubmed-observation-pmid-23243269-2021-10-21-160405f6760a"></a>
- **Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. · retained source version 1:2021-10-21:current:160405f6760aa9ecbe5668b2ad513bc7fa42d7c795c4e8e6c06edb10a8a5f63a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23243269/) (`pubmed-observation-pmid-23243269-2021-10-21-160405f6760a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23243269-peginesatide-v1 SHA-256: 1ed287be9f8cb90d55e4e1b5c612f7a8f60c11432b850c10eaa8e7b4612d57ed.

---

<a id="pubmed-pmid-23343061-peginesatide-v1"></a>

## Peginesatide in patients with anemia undergoing hemodialysis.

> PubMed lists PMID 23343061 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23343061-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23343061-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23343061-peginesatide-v1
- Content SHA-256: `fbafabd8c58eb200d2fe6d5537f3037e55e725d6c67b3bac0d750c731df8ba67`

### Claims and source pins

#### Headline

Peginesatide in patients with anemia undergoing hemodialysis. ([`pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26`](#source-pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26))

#### Summary

PubMed lists PMID 23343061 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26`](#source-pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26))

#### Paragraph 1

PubMed lists PMID 23343061 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26`](#source-pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26`](#source-pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26))

### Sources

<a id="source-pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26"></a>
- **Peginesatide in patients with anemia undergoing hemodialysis. · retained source version 1:2026-05-18:current:0e7025afeb2646063f31f2a358196d9c8166a036c1a3a6c64927a89ebd31a747** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23343061/) (`pubmed-observation-pmid-23343061-2026-05-18-0e7025afeb26`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide in patients with anemia undergoing hemodialysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23343061-peginesatide-v1 SHA-256: fbafabd8c58eb200d2fe6d5537f3037e55e725d6c67b3bac0d750c731df8ba67.

---

<a id="pubmed-pmid-23343062-peginesatide-v1"></a>

## Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.

> PubMed lists PMID 23343062 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23343062-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23343062-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23343062-peginesatide-v1
- Content SHA-256: `aad50f64ff1ff096877b3718808a35e0ec10d812c8e6e875ffd7692b9b28d320`

### Claims and source pins

#### Headline

Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. ([`pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462`](#source-pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462))

#### Summary

PubMed lists PMID 23343062 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462`](#source-pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462))

#### Paragraph 1

PubMed lists PMID 23343062 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-01-24 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462`](#source-pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462`](#source-pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462))

### Sources

<a id="source-pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462"></a>
- **Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. · retained source version 1:2026-05-18:current:fe38b7444462da53a614302cb4b6080c4225bb061a79fe7afe7dfd618c5bdc1b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23343062/) (`pubmed-observation-pmid-23343062-2026-05-18-fe38b7444462`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23343062-peginesatide-v1 SHA-256: aad50f64ff1ff096877b3718808a35e0ec10d812c8e6e875ffd7692b9b28d320.

---

<a id="pubmed-pmid-23594010-peginesatide-v1"></a>

## Peginesatide for anemia in chronic kidney disease.

> PubMed lists PMID 23594010 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23594010-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23594010-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23594010-peginesatide-v1
- Content SHA-256: `85cb78e21cb7fedd7b802fa5a9e5c59f86d1d7a23f7d1be99787125fd3817584`

### Claims and source pins

#### Headline

Peginesatide for anemia in chronic kidney disease. ([`pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e`](#source-pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e))

#### Summary

PubMed lists PMID 23594010 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e`](#source-pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e))

#### Paragraph 1

PubMed lists PMID 23594010 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e`](#source-pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e`](#source-pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e))

### Sources

<a id="source-pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e"></a>
- **Peginesatide for anemia in chronic kidney disease. · retained source version 1:2018-12-02:current:9f0036084c2ebed3ee94ae6b7855622237c54acf5cb1edc03a2dd4a4e1727287** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23594010/) (`pubmed-observation-pmid-23594010-2018-12-02-9f0036084c2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide for anemia in chronic kidney disease." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23594010-peginesatide-v1 SHA-256: 85cb78e21cb7fedd7b802fa5a9e5c59f86d1d7a23f7d1be99787125fd3817584.

---

<a id="pubmed-pmid-23594011-peginesatide-v1"></a>

## Peginesatide for anemia in chronic kidney disease.

> PubMed lists PMID 23594011 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23594011-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23594011-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23594011-peginesatide-v1
- Content SHA-256: `284eb758901c8deaa2499fc8dd96600ef398d0a4dc0a8f1ab4c1b6515ab7b3b3`

### Claims and source pins

#### Headline

Peginesatide for anemia in chronic kidney disease. ([`pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b`](#source-pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b))

#### Summary

PubMed lists PMID 23594011 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b`](#source-pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b))

#### Paragraph 1

PubMed lists PMID 23594011 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2013-04-18 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b`](#source-pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b`](#source-pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b))

### Sources

<a id="source-pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b"></a>
- **Peginesatide for anemia in chronic kidney disease. · retained source version 1:2018-12-02:current:c32f638a3c1ba4d25eb7e582ef4c9e4808296e72c1b4b72402fc9465575e3e28** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23594011/) (`pubmed-observation-pmid-23594011-2018-12-02-c32f638a3c1b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide for anemia in chronic kidney disease." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23594011-peginesatide-v1 SHA-256: 284eb758901c8deaa2499fc8dd96600ef398d0a4dc0a8f1ab4c1b6515ab7b3b3.

---

<a id="pubmed-pmid-23675762-peginesatide-v1"></a>

## Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star?

> PubMed lists PMID 23675762 in Expert opinion on pharmacotherapy as Editorial, with publication-date metadata of 2013-05-16 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23675762-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23675762-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23675762-peginesatide-v1
- Content SHA-256: `113a309d2fd57d784dc5c36597d069279158c116e15cbe2878776b8e5381b863`

### Claims and source pins

#### Headline

Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star? ([`pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba`](#source-pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba))

#### Summary

PubMed lists PMID 23675762 in Expert opinion on pharmacotherapy as Editorial, with publication-date metadata of 2013-05-16 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba`](#source-pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba))

#### Paragraph 1

PubMed lists PMID 23675762 in Expert opinion on pharmacotherapy as Editorial, with publication-date metadata of 2013-05-16 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba`](#source-pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba`](#source-pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba))

### Sources

<a id="source-pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba"></a>
- **Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star? · retained source version 1:2017-11-16:current:68d259f36fbad1dbedfe952f3eb38e6ec10a762bf12d12b150db61eecd5a4099** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23675762/) (`pubmed-observation-pmid-23675762-2017-11-16-68d259f36fba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23675762-peginesatide-v1 SHA-256: 113a309d2fd57d784dc5c36597d069279158c116e15cbe2878776b8e5381b863.

---

<a id="pubmed-pmid-23810692-peginesatide-v1"></a>

## On peginesatide and anemia treatment in CKD.

> PubMed lists PMID 23810692 in American journal of kidney diseases : the official journal of the National Kidney Foundation as Editorial, Comment, with publication-date metadata of 2013-06-28 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23810692-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23810692-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23810692-peginesatide-v1
- Content SHA-256: `91c63db09539ee00c7b24c29be9aa8f5b8cd3557292caa36fa2608aa1a3c253b`

### Claims and source pins

#### Headline

On peginesatide and anemia treatment in CKD. ([`pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff`](#source-pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff))

#### Summary

PubMed lists PMID 23810692 in American journal of kidney diseases : the official journal of the National Kidney Foundation as Editorial, Comment, with publication-date metadata of 2013-06-28 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff`](#source-pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff))

#### Paragraph 1

PubMed lists PMID 23810692 in American journal of kidney diseases : the official journal of the National Kidney Foundation as Editorial, Comment, with publication-date metadata of 2013-06-28 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff`](#source-pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff`](#source-pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff))

### Sources

<a id="source-pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff"></a>
- **On peginesatide and anemia treatment in CKD. · retained source version 1:2018-12-02:current:9a356f2cf3ffe632c0dffc4b7e9c2d640f978f55fde09223da624024a0011639** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23810692/) (`pubmed-observation-pmid-23810692-2018-12-02-9a356f2cf3ff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "On peginesatide and anemia treatment in CKD." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-23810692-peginesatide-v1 SHA-256: 91c63db09539ee00c7b24c29be9aa8f5b8cd3557292caa36fa2608aa1a3c253b.

---

<a id="pubmed-pmid-24023516-peginesatide-v1"></a>

## Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.

> PubMed lists PMID 24023516 in International journal of nanomedicine as Journal Article, Review, with publication-date metadata of 2013-08-26 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24023516-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24023516-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-24023516-peginesatide-v1
- Content SHA-256: `66c9796f0b7b137f2a1c814ef9320294177b507d10f8ac053d1edc4501f779df`

### Claims and source pins

#### Headline

Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. ([`pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8`](#source-pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8))

#### Summary

PubMed lists PMID 24023516 in International journal of nanomedicine as Journal Article, Review, with publication-date metadata of 2013-08-26 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8`](#source-pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8))

#### Paragraph 1

PubMed lists PMID 24023516 in International journal of nanomedicine as Journal Article, Review, with publication-date metadata of 2013-08-26 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8`](#source-pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8`](#source-pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8))

### Sources

<a id="source-pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8"></a>
- **Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. · retained source version 1:2021-10-21:current:27faf7add2b8299bf25a22613363d3fb51d5a8835786ac40bd4dafda128b647c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24023516/) (`pubmed-observation-pmid-24023516-2021-10-21-27faf7add2b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-24023516-peginesatide-v1 SHA-256: 66c9796f0b7b137f2a1c814ef9320294177b507d10f8ac053d1edc4501f779df.

---

<a id="pubmed-pmid-24584613-peginesatide-v1"></a>

## Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis.

> PubMed lists PMID 24584613 in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-03-01 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24584613-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24584613-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-24584613-peginesatide-v1
- Content SHA-256: `c37ea18b8e394aee9f884bc070d32c1ef513d1b272e37648b8e6a2e29906191d`

### Claims and source pins

#### Headline

Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis. ([`pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0`](#source-pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0))

#### Summary

PubMed lists PMID 24584613 in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-03-01 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0`](#source-pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0))

#### Paragraph 1

PubMed lists PMID 24584613 in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-03-01 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0`](#source-pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0`](#source-pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0))

### Sources

<a id="source-pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0"></a>
- **Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis. · retained source version 1:2021-10-21:current:d3f15ad296f09277c682397fd71a5d47e9248b50149ef344fe5ec5907a80fe55** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24584613/) (`pubmed-observation-pmid-24584613-2021-10-21-d3f15ad296f0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-24584613-peginesatide-v1 SHA-256: c37ea18b8e394aee9f884bc070d32c1ef513d1b272e37648b8e6a2e29906191d.

---

<a id="pubmed-pmid-27279382-peginesatide-v1"></a>

## Watch out for a revival of peginesatide in sports.

> PubMed lists PMID 27279382 in Drug testing and analysis as Journal Article, with publication-date metadata of 2016-06-09 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27279382-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27279382-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-27279382-peginesatide-v1
- Content SHA-256: `2bfdd0d142bc8b10746dd77a1c663564f3a536f4fe624fe235146a3447383917`

### Claims and source pins

#### Headline

Watch out for a revival of peginesatide in sports. ([`pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32`](#source-pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32))

#### Summary

PubMed lists PMID 27279382 in Drug testing and analysis as Journal Article, with publication-date metadata of 2016-06-09 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32`](#source-pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32))

#### Paragraph 1

PubMed lists PMID 27279382 in Drug testing and analysis as Journal Article, with publication-date metadata of 2016-06-09 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32`](#source-pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32`](#source-pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32))

### Sources

<a id="source-pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32"></a>
- **Watch out for a revival of peginesatide in sports. · retained source version 1:2017-11-16:current:7f266d61ff3218b119b68cdab94ec6a0b8cd6299171ca8cdab2aa53b2d13930e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27279382/) (`pubmed-observation-pmid-27279382-2017-11-16-7f266d61ff32`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Watch out for a revival of peginesatide in sports." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-27279382-peginesatide-v1 SHA-256: 2bfdd0d142bc8b10746dd77a1c663564f3a536f4fe624fe235146a3447383917.

---

<a id="pubmed-pmid-27551882-peginesatide-v1"></a>

## Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise.

> PubMed lists PMID 27551882 in Expert opinion on drug safety as Comparative Study, Journal Article, Review, with publication-date metadata of 2016-08-23 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27551882-peginesatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27551882-peginesatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-27551882-peginesatide-v1
- Content SHA-256: `6e6436c41ab28845110d414b99a39e8145deec04c91d6145efb74772ae5430a9`

### Claims and source pins

#### Headline

Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. ([`pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e`](#source-pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e))

#### Summary

PubMed lists PMID 27551882 in Expert opinion on drug safety as Comparative Study, Journal Article, Review, with publication-date metadata of 2016-08-23 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e`](#source-pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e))

#### Paragraph 1

PubMed lists PMID 27551882 in Expert opinion on drug safety as Comparative Study, Journal Article, Review, with publication-date metadata of 2016-08-23 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e`](#source-pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e`](#source-pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e))

### Sources

<a id="source-pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e"></a>
- **Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. · retained source version 1:2018-11-13:current:abd70eff690e4ed3dbb951a0c9650ffe097ffaf08cbca2a24f48c9f781954de0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27551882/) (`pubmed-observation-pmid-27551882-2018-11-13-abd70eff690e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/peginesatide.json#pubmed-pmid-27551882-peginesatide-v1 SHA-256: 6e6436c41ab28845110d414b99a39e8145deec04c91d6145efb74772ae5430a9.

